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ABSTRACT: Weaver syndrome (WS) is a rare congenital
disorder characterized by generalized overgrowth, macro-
cephaly, specific facial features, accelerated bone age, in-
tellectual disability, and susceptibility to cancers. De novo
mutations in the enhancer of zeste homolog 2 (EZH2)
have been shown to cause WS. EZH2 is a histone methyl-
transferase that acts as the catalytic agent of the polycomb-
repressive complex 2 (PRC2) to maintain gene repression
via methylation of lysine 27 on histone H3 (H3K27).
Functional studies investigating histone methyltransferase
activity of mutant EZH2 from various cancers have been
reported, whereasWS-associated mutations remain poorly
characterized. To investigate the role of EZH2 in WS, we
performed functional studies using artificially assembled
PRC2 complexes containing mutagenized human EZH2
that reflected the codon changes predicted from patients
with WS. We found that WS-associated amino acid alte-
rations reduce the histone methyltransferase function of
EZH2 in this in vitro assay. Our results support the hy-
pothesis that WS is caused by constitutional mutations in
EZH2 that alter the histone methyltransferase function
of PRC2. However, histone methyltransferase activities
of different EZH2 variants do not appear to correlate di-
rectly with the phenotypic variability betweenWS patients
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and individuals with a common c.553G>C (p.Asp185His)
polymorphism in EZH2.
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Introduction
Thehistonemethyltransferase EZH2 (enhancer of zeste homolog 2)
(MIM #601573) is a key epigenetic regulator inmammals. This pro-
tein forms the catalytic subunit of the polycomb-repressive complex
2 (PRC2) [Kuzmichev et al., 2002], and is thought to suppress gene
transcription epigenetically by adding up to three methyl groups
onto lysine residue 27 of histone H3 (H3K27). Epigenetic silencing
via EZH2-mediated histone methylation is further supported by
the fact that some mutations at the level of H3K27 can inhibit the
activity of PRC2 [Lewis et al., 2013; Pengelly et al., 2013].
Somatic mutations of EZH2 in circulating white blood cells have
been shown to be extremely common in hematological malignan-
cies [Lund et al., 2014]. Sequencing of human diffuse large B-cell
and non-Hodgkin lymphomas revealed recurrent somatic muta-
tions at positions Tyr646, Ala682, and Ala692 (or Tyr641, Ala677,
and Ala687 in the shorter EZH2 isoform as referenced in the
original publications) [Morin et al., 2010; Majer et al., 2012; Mc-
Cabe et al., 2012a]. The most frequently mutated residue, tyrosine
at position 646, has been reported as mutated to phenylalanine
(p.Tyr646Phe), asparagine (p.Tyr646Asn), histidine (p.Tyr646His),
and serine (p.Tyr646Ser) [Morin et al., 2010]. All of these heterozy-
gous single amino acid substitutions have been shown to change the
substrate specificity and favor trimethylation ofH3K27 (H3K27me2
→H3K27me3) over monomethylation (H3K27me0→ H3K27me1)
C© 2015 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
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and dimethylation (H3K27me1→ H3K27me2). When combined
with the activity of the wild-type (WT) EZH2 copy, which has
high affinity for unmethylated H3K27me0 and medium affinity
for monomethylated H3K27me1, this results in an overall gain-of-
function of EZH2 [Sneeringer et al., 2010; Yap et al., 2011]. Unlike
for Tyr646, mutations at the other two sites have only been reported
as specific amino acid substitutions, p.Ala682Gly [McCabe et al.,
2012a] and p.Ala692Val [Majer et al., 2012].These two alterations
also showgain-of-function activity but appear to favor different sub-
strates. p.Ala682Gly promotes methyltransferase activity of nearly
equal efficiency for all three substrates (H3K27me0/me1/me2),
thereby resulting in hypertrimethylation of H3K27 [McCabe et al.,
2012a]. By contrast, p,Ala692Val reduces monomethylation and en-
hances dimethylation of H3K27 while leaving trimethylation vir-
tually unchanged in vitro [Majer et al., 2012], although global
levels of H3K27me3 were found to be increased in a tumor-derived
p.Ala692Val mutant cell line, or when this mutant was transiently
expressed in a cell line with an EZH2 WT background [Ott et al.,
2014]. Given that additional data support the increased activity of
EZH2 in other cancers, possibly independent of its assembly into
the PRC2 complex [Xu et al., 2012], there is intense interest in
developing EZH2 inhibitors as potential chemotherapeutic agents
[Knutson et al., 2012; McCabe et al., 2012b; Qi et al., 2012; Knut-
son et al., 2012; Tan et al., 2014; Van Aller et al., 2014]. Targeting
of other proteins in the complex, such as EED and SUZ12, may
also become a useful therapeutic strategy [Tan et al., 2014], as may
disruption of proper PRC2 complex assembly [Kim et al., 2013a].
Notably, though, inactivating mutations have been found at multi-
ple sites throughout the EZH2 gene in myeloid disorders and acute
lymphoblastic leukemia [Ernst et al., 2010; Makishima et al., 2010;
Guglielmelli et al., 2011; Ntziachristos et al., 2012; Score et al., 2012;
Zhang et al., 2012; The Cancer Genome Atlas Research Network,
2013], suggesting that some neoplasms may not respond well to
EZH2 inhibition.
Recently, we and others have shown that de novo germline mu-
tations in EZH2 cause Weaver syndrome (WS; MIM #277590), a
rare but well-described developmental disorder of prenatal onset
that features intellectual disability, tall stature, macrocephaly, accel-
erated bone growth and maturation, and a susceptibility to cancers
including hematological malignancies [Tatton-Brown et al., 2011;
Gibson et al., 2012; Tatton-Brown et al., 2013; Tatton-Brown and
Rahman, 2013]. Aspects of this phenotype can be explained by
the role of Ezh2 in craniofacial skeleton formation [Schwarz et al.,
2014]. Though cerebral malformations were not part of the original
description of WS [Weaver et al., 1974], recent clinical reports have
documented the presence of neuronal migration disorders in asso-
ciation with physical features ofWS [Freeman et al., 1999; Al-Salem
et al., 2013; Tatton-Brown et al., 2013]. In the case reported by Al-
Salem et al. (2013), polymicrogyria was proven to be associated with
a de novomutation in EZH2, confirming the diagnosis of WS in this
patient. In the more recent case reported by Tatton-Brown et al.
(2013), pachy- and polymicrogyria were associated with a trunca-
ting variant in EZH2, classified as likely pathogenic because parental
samples were unavailable.
Given that both gain-of-function and loss-of-functionmutations
in EZH2 have been associated with human neoplastic disease when
acquired during life in somatic cells [Ernst et al., 2010; Yap et al.,
2011; McCabe et al., 2012a; Ntziachristos et al., 2012; Lund et al.,
2014], we hypothesized that germline de novo mutations causative
of WS would alter EZH2 activity within the PRC2 complex. We fur-
ther hypothesized that more severe clinical features of WS (such as
cerebral migration defects, or the development of leukemia) might
be specifically associated with more significant changes in PRC2-
mediated methyltransferase activity conferred by individual muta-
tions in EZH2.
Materials and Methods
To test our hypothesis, we designed recombinant human EZH2
proteins, had them preassembled into PRC2 complexes (BPS Bio-
science, San Diego CA), and tested their activity in vitro using a
well-accepted in vitro assay [Ernst et al., 2010; Yap et al., 2011; Score
et al., 2012].Mutant EZH2–PRC2 complexes were selected for study
based on the rare de novo variants observed in our original three
patients [Gibson et al., 2012] and among other patients with WS
identified since. Two other variants that had been observed in pa-
tients with both WS and neoplastic disease [Tatton-Brown et al.,
2011] were also selected.
Patients
Clinical data presented here were collected by the physicians who
referred the patients to our study. Participating families provided
informed consent, and this study was approved by the joint Clinical
Research Ethics Board of the University of British Columbia and
British Columbia Children’s Hospital.
Sequencing
Sanger sequencing was performed on PCR products from ge-
nomic DNA. PCR primers were used to amplify the 19 coding
exons of EZH2 (exons 2–20; primers available upon request)
[Gibson et al., 2012]. All primer pairs were confirmed to be
specific to the EZH2 gene on chromosome 7 (NC 000007.13:
148504464–148581441) rather than the pseudogene on chromo-
some 21 (NC 000021.8: 36971977–36972553) using the BLAST
function on NCBI at http://www.ncbi.nlm.nih.gov//blast/Blast.cgi
(GRCh37.p13 assembly). NCBI Reference sequence NM 004456.4
is available from GenBank. This corresponds to the longest iso-
form of EZH2. All nomenclature of described sequence vari-
ants is based on this sequence and follows the guidelines des-
cribed in http://www.hgvs.org/mutnomen/. Population frequen-
cies for each variant were investigated in the dbSNP database,
searchable at http://www.ncbi.nlm.nih.gov/projects/SNP/, and the
exome variant server, found at http://evs.gs.washington.edu/EVS/.
Functional predictions for previously undescribed variants were
done using the PROVEAN and SIFT tools, available at
http://provean.jcvi.org/index.php (PROVEAN v1.1.3). Detailed
prediction scores are provided in Supp. Table S1. All described
pathogenic variants have been submitted to the LOVD locus-specific
database and can be found at http://www.lovd.nl/EZH2.
Histone Methyltransferase Assay
Core histones were purchased from EMD Millipore (13-107;
Billerica MA) and used as methyl acceptors in most of our in vitro
reactions. This substrate contains a mix of all core histones and H3
peptides at different methylation states, thereby recapitulating the
heterogeneity of endogenous nucleosomes. In an alternative assay,
biotinylated peptides (mimicking the H3 tail, H3[21–44]) that had
been unmethylated (H3K27me0), monomethylated (H3K27me1)
or dimethylated (H3K27me2) were used as substrate (Supp. Fig.
S1). We purchased PRC2 complexes containing WT EZH2 (51004)
or mutant EZH2 from BPS Bioscience [Morin et al., 2010]. Methyl-
transferase assays were done using a commonly used kit (17–330;
EMD Millipore) [Ernst et al., 2010; Yap et al., 2011; Score et al.,
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2012] as per manufacturer’s instructions. We incubated 250 ng
of individual HMTase complexes separately with 0.67 μM 3H-S-
adenosyl-methionine (3H-SAM) (Perkin Elmer, WalthamMA) and
2 μg core histones (or 1 μM peptide), in 50 mM Tris–HCl, pH 9.0,
and 0.5 mM DTT for 30 min at 30°C in a 10 μl volume. Excess
volumes of 3H-SAM, core histones, and a longer incubation were
also tested (Supp. Fig. S2). In all reactions, five or eight microliters
were spotted on a P81 square paper (Millipore), washed (three times
with 10% tricholoracetic acid and once with 95% ethanol) to re-
move unincorporated 3H-Met, air-dried overnight, placed in a glass
scintillation vial with 3 ml of scintillation fluid (ScintiSafe Econo1
SX20-5 or Scintisafe 30% SX23-5; Fisher Chemical, Waltham MA),
and counted on a 1900TR Liquid Scintillation Analyzer (Perkin
Elmer) or LS6500 Multi-Purpose Scintillation Counter (Beckman
Coulter, Brea CA). Normalized counts represent the subtraction of
background counts (i.e., control tubes with no enzyme added) from
total counts.
Results
Probands
Probands 1, 2, and 3 were described previously [Gibson
et al., 2012]. The mutations identified in EZH2 were c.457 459
delTAT (p.Tyr153del), c.2080C>T (p.His694Tyr), and c.394C>T
(p.Pro132Ser), respectively.
Proband4wasoriginallypublished in2001 [Huffmanet al., 2001].
More detailed clinical features are described in Supp. Table S2.Using
Sanger sequencing, we identified a c.394C>T (p.Pro132Ser) muta-
tion in EZH2, an alteration previously described in proband 3 from
our cohort [Gibson et al., 2012] and not detected in any of the
parents of probands 3 or 4. Proband 4 had a stage 4S neuroblas-
toma, which subsequently underwent spontaneous resolution, as
was commonly observed for this type of tumor [Huffman et al.,
2001]. At this time, a predisposition for neoplasm development
in WS and other overgrowth syndromes was already recognized
[Huffman et al., 2001]. This patient also presented with congenital
heart defects. Recently, de novo mutations in histone-modifying
genes have been implicated in many cases of congenital heart
disease [Zaidi et al., 2013], further supporting a role for EZH2
in this individual’s phenotype.
The clinical features of proband 5 are summarized in Supp. Table
S2. The most striking and unusual feature is polymicrogyria. Pho-
tographs andMRI brain images are presented in Figure 1. A clinical
summary is provided in the Supp. Text along with fetal ultrasound
results documenting prenatal onset of excessive growth (Supp. Table
S3). We identified a c.2050C>T (p.Arg684Cys) mutation in EZH2,
confirmed to be de novo by trio-based testing at the BC Children’s
Hospital Clinical Molecular Genetics Lab. This mutation was pre-
viously described in four other WS patients [Tatton-Brown et al.,
2011], and thus appears to be a relatively frequent cause of WS.
The clinical features of probands 6 and 7 are summarized in Supp.
Table S2. Further clinical information is provided in the Supp. Text.
In both unrelated patients, we identified a c.398A>G (p.Tyr133Cys)
de novomutation in EZH2. This mutation was predicted damaging
by PROVEAN/SIFT (Supp. Table S1).
We also detected the c.553G>C (p.Asp185His) variant in EZH2
in individuals referred to our WS-like cohort. This variant was pre-
dicted damaging by SIFT but not by PROVEAN (Supp. Table S1).
Clinical features of carriers of this p.(Asp185His) variant (cases 15,
40, 53, 73, and 95) are summarized in Supp. Table S4 and further
clinical information is provided in the Supp. Text. Other members
of their families were tested at this locus and in all cases the variant
was found to be inherited from one of the parents (Supp. Table S4).
p.(Asp185His) is reported in dbSNP (rs2302427C>G) with minor
allele frequencies of 8% in the 1000 Genomes phase 1 population,
6% in theExomeVariant Server, and 7.7% in ahealthy ancestrally di-
verse cohort screened for common variants in cancer-susceptibility
genes [Bodian et al., 2014]. Because of its frequency in the gen-
eral population, the p.(Asp185His) variant cannot in isolation be
causative of WS.
EZH2 Mutations in WS Impair Histone Methyltransferase
Activity In Vitro
In order to determine the functional impact of the EZH2
mutations observed in WS, EZH2 mutant proteins correspon-
ding to the mutations observed in WS patients were expressed
in vitro and then assembled together with other artificially ex-
pressed members of the PRC2 complex (EED/SUZ12/RbAp48
and AEBP2). Preassembly into the PRC2 complex was neces-
sary because EZH2 requires other members of PRC2 for activ-
ity on nucleosomes [Kuzmichev et al., 2002]. The mutations stu-
died included those identified within our cohort: p.(Tyr153del),
p.(His694Tyr), p.(Pro132Ser), p.(Arg684Cys), and p.(Tyr133Cys).
The p.(Ala682Thr) and p.(Glu745Lys) mutations were also of in-
terest because of their associations with neuroblastoma, acute lym-
phoblastic leukemia, and lymphoma inWS patients [Tatton-Brown
et al., 2011]. As mentioned above, we also included the common
variant p.(Asp185His).WTEZH2was used as a positive control, and
the methyltransferase-inactive mutant EZH2 p.(Phe672Ile) (equiv-
alent to the inactive fly mutant allele E(z)son1 described in Joshi
et al. [2008]) was used as a negative control. We then measured
incorporation of tritiated methyl groups from 3H-SAM onto mixed
core histones in the presence of each EZH2-PRC2 complex (Fig. 2;
Supp. Fig. S3 and Supp. Table S5A). As expected, WT EZH2–PRC2
complex catalyzed the incorporation of 3H into core histones, con-
sistent with the model whereby it uses 3H-SAM as the methyl donor
and nucleosomes as the recipient substrates for histonemethylation
[Kuzmichev et al., 2002]. In contrast, PRC2 complexes containing
WS-associatedEZH2mutants showed reducedhistonemethyltrans-
ferase activity in vitro (Fig. 2; Supp. Fig. S3 and Supp. Table S5A),
suggesting that EZH2 mutations associated with WS are loss-of-
function (hypomorphic) mutations.
The Common p.(Asp185His) Variant Also Appears to Impair
Histone Methyltransferase Activity In Vitro
Surprisingly, EZH2 p.(Asp185His) also showed impaired histone
methyltransferase activity in this in vitro assay (Fig. 2A; Supp. Fig.
S3). Based on the frequency of this variant and the rarity of WS,
p.(Asp185His) cannot by itself be causative of WS. However, based
on the number of replicates we performed under varied conditions
(Supp. Fig. S2 and Supp. Tables S5B and C), we believe this result to
be reproducible and to reflect accurately the activity of this enzyme
variant under these artificial conditions.
Discussion
Expanding the Phenotype of WS to Include Neuronal
Migration Disorders
Brain imaging in proband 5 (Fig. 1G) was consistent with that
reported on two prior occasions in different children with WS
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Figure 1. Weaver syndrome proband with polymicrogyria described in this study. A: Proband 5 is shown at 2, 4, 6, 8, 12, and 19 months. B: Both
sides of the hand are shown at 12 months to illustrate the prominent palmar crease. C: At 27 months, face with prominent rosy cheeks, profile and
ears are shown to confirm the dimple is only present behind the right ear. D: At 31 months, mild camptodactyly is seen on the toes and a third nipple
is apparent. E: Full torso and full body are also shown at 31 months. F: X-rays of the hand at 11½months and the knee at 10½months are indicative
of advanced bone age. G:MRI done at 5 days of age illustrates asymmetric perisylvian polymicrogyria.
[Freeman et al., 1999; Al-Salem et al., 2013]. In each previous case,
and in our case, there was asymmetric perisylvian polymicrogyria
that appeared more severe on the right side, as well as mildly
enlarged lateral ventricles. The report by Freeman et al. (1999)
described pachygyria, but based on review of the published images
(W. Dobyns), we believe the findings are more consistent with
perisylvian polymicrogyria. The image shown in the report by
Al-Salem et al. (2013) demonstrates enlarged extra-axial fluid
spaces over the brain, similar in appearance to the polymicrogyria
observed among megalencephaly syndromes associated with
PI3K-AKT pathway mutations [Mirzaa et al., 2012]. However,
neither hydrocephalus nor Chiari malformations were seen in these
WS patients. Tatton-Brown et al. (2013) also reported a case with
pachy- and polymicrogyria, but no images were published.
Our proband 5 has the recurrent p.(Arg684Cys) de novo mu-
tation, the patient with polymicrogyria and WS described by Al-
Salem et al. (2013) was shown to have a de novo p.(Glu745Lys)
mutation, and the patient from Tatton-Brown et al. (2013) had an
EZH2 variant predicted to truncate the protein at position 732. The
association of polymicrogyria with WS in four independent cases,
two of which have molecular confirmation of de novo mutations
in different exons of EZH2 and another of which has a trunca-
ting variant in the last exon, strongly supports a causal association
between EZH2 mutations and neuronal migration defects in some
patients with WS. EZH2 has been shown to control the decision
between self-renewal and differentiation in the cerebral cortex, and
inhibition of PRC2 complex activity had been shown to shift the
balance toward differentiation [Pereira et al., 2010]. Furthermore,
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Figure 2. Weaver syndrome mutants are impaired in their histone methyltransferase activity in vitro. Histone methyltransferase reactions were
performed using 2 μg purified core histones and 0.67 μM 3H-S-adenosyl-methionine (3H-SAM). Each reaction was incubated with 250 ng of either
wild-type (WT) or a mutant HMTase complex (or no enzyme controls). Histonemethyltransferase activity wasmeasured based on the incorporation
of 3H-labeled methyl groups, represented in scintillation counts per minute. Counts were normalized by subtracting background counts (i.e., no
enzyme) from the total counts. A: Incorporation of tritiated methyl groups from 3H-SAM onto core histones is shown for each complex: EZH2
WT •, p.(Phe672Ile) ×, p.(Pro132Ser) , p.(Tyr153del) , p.(His694Tyr) , p.(Glu745Lys) , p.(Ala682Thr) , p.(Arg684Cys) , p.(Tyr133Cys) ,
and p.(Asp185His) . Error bars represent standard deviation (SD) within the groups “EZH2 WT” and “EZH2 mutants.” Unpaired t-test showed
statistically significant difference between the two groups (P value < 0.0001). B: Incorporation of tritiated methyl groups from 3H-SAM onto core
histones is shown for the positive control EZH2 WT, the negative control EZH2 (p.Phe672Ile), and the mutant complex with activity closest to WT,
namely, EZH2 (p.Pro132Ser). Error bars represent SD of four independent replicates for the controls, and three independent replicates for the
mutant EZH2 (p.Pro132Ser). One-way ANOVA showed statistically significant difference between all groups (overall P value < 0.0001; P values
between WT and p.(Phe672Ile), between p.(Phe672Ile) and p.(Pro132Ser), and between WT and p.(Pro132Ser) were all <0.05).
EZH2 has also been shown to orchestrate neuronal migration in the
cortico-ponto-cerebellar pathway in mice [Di Meglio et al., 2013].
The possibility that diminished PRC2 complex activity could lead to
premature neuronal differentiation, possibly at ectopic sites along
the normalmigration pathway, offers a plausible explanation for the
cortical patterning defects seen in patients with WS and pachy- or
polymicrogyria.
Thus, in addition to their known risk for neoplastic disease, pa-
tients with WS should be considered to be at risk for neuronal
migration disorders, and physicians should have a low threshold
for ordering cranial imaging studies. Similarly, children with over-
growth and cerebral migration disorders could be tested for rare
variants in EZH2, and physicians performing prenatal diagnosis
in the context of a fetus with polymicrogyria should consider the
possibility of WS.
Given the large number of individuals now being studied with
high-throughputnext-generation sequencing, rare variants inEZH2
that are discovered through targeted sequencing panels, exome se-
quencing, or whole-genome sequencing should be considered care-
fully in the context of clinical findings such as overgrowth pheno-
types, cerebral malformations, and neoplastic disease. For highly
heterogeneous disorders such as overgrowth syndromes, techniques
such as exome sequencing are becoming cost-effective for diagnosis
at an early stage of the workup. An estimate of diagnostic costs in-
curred during the workup of proband 5 is presented in Supp. Table
S6, for theoretical comparison to early exome sequencing (though
in his particular case, EZH2was selected on a candidate gene basis).
WSMutations and Neoplastic Disease
With somatic mutations in EZH2 having been associated to both
gain and loss of histonemethyltransferase function, itwas important
to investigate mutations found in WS patients who had also deve-
loped malignancies. To date, none of the three cases from our ori-
ginal report have been diagnosed with neoplastic disease. However,
proband 4 had a nonmetastatic stage 4S neuroblastoma in his left
adrenal gland. Our functional analysis of the EZH2 p.(Pro132Ser)
mutant complex suggested a loss-of-function effect, consistent with
a previous report of this variant in the context of myeloid disorders
[Guglielmelli et al., 2011]. Proband 6 had a prenatal neuroblastoma
in the right adrenal gland that was successfully removed surgically
shortly after birth, and the EZH2 p.(Tyr133Cys) mutant complex
also appeared to be loss-of-function in our assay. The other twomu-
tant complexes containing mutations found in patients with malig-
nancies, EZH2 p.(Arg682Thr), and p.(Glu745Lys) [Tatton-Brown
et al., 2011], also showed loss-of-function in vitro, suggesting that
the mechanism driving cancer in WS patients resembles that of
myeloid disorders and acute lymphoblastic leukemia rather than
that of diffuse large B-cell and non-Hodgkin lymphomas. Further-
more, the p.(Arg684Cys) mutation reported in several independent
cases [Tatton-Brown et al., 2011] and identified in proband 5, which
has not yet been associatedwithmalignancy development inWS but
appears to be a true recurrent mutation, had already been described
as likely inactivating in myeloid disorders [Ernst et al., 2010]. Over-
all, all de novoWS-associatedEZH2mutations showed impaired his-
tone methyltransferase activity in vitro, particularly with reduced
ability to monomethylate H3K27 (Supp. Fig. S1 and Supp. Table
S5D). Impaired histone methyltransferase activity had previously
been observed among NSD1 mutations causing Sotos syndrome
(MIM #117550) [Qiao et al., 2011; Kudithipudi et al., 2014], which
is another overgrowth syndrome that shares significant phenotypic
overlapwithWS [Tatton-Brown andRahman, 2013]. Based on these
results, we suggest that EZH2 inhibitors currently being developed
against various cancers [Knutson et al., 2012; McCabe et al., 2012b;
Qi et al., 2012; Knutson et al., 2013] may not be of specific benefit in
WS. Importantly, we did not assay PRC2-independent functions of
EZH2, so additional complexity in the functional effects of disease-
associated EZH2 mutations remains to be unraveled.
Methyltransferase Activity of p.(Asp185His)
We identified the p.(Asp185His) variant in five individuals who
were referred for WS-like features, including macrocephaly. This
variant has been found inmultiple healthy controls, aswell as among
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individuals affected with generalized overgrowth or acute leukemia
[Tatton-Brown et al., 2011; Grossmann et al., 2012]. Importantly,
recent genome-wide association studies for human height and for
infant head circumference have not identified this variant as a risk
factor for either of these quantitative traits [Taal et al., 2012; Wood
et al., 2014]. Thus, population genetic evidence supports the clas-
sification of the p.(Asp185His) variant as a common, benign SNP
(single-nucleotide polymorphism). In this context, the fact that our
functional work suggests impaired histone methyltransferase acti-
vity for this mutant is notable. Based on careful repetition of our
assays with different lot numbers of the WT protein and under va-
ried conditions (Fig. 2; Supp. Figs. S2 and S3), we do believe our
in vitro results to be reproducible. Given the reproducibility of our
assay in our hands and the use of a similar assay by multiple other
groups, we do not believe the low methyltransferase activity exhi-
bited by the p.(Asp185His) protein variant in this assay is indica-
tive of experimental error. Rather, we believe that our results reflect
the true activity of this variant under this select set of experimen-
tal conditions. Nevertheless, given the lack of a specific phenotype
for p.(Asp185His) carriers, these in vitro results may not reflect
its true activity in vivo. On this basis, we must conclude that this
particular in vitro assay cannot be used in isolation to assess the po-
tential pathogenicity of novel EZH2 variants. Instead, pathogenicity
should be assessed based on the sum total of available evidence from
family-specific cosegregation with disease phenotypes, population
genetics, and, where available, other orthogonal lines of functional
evidence. The possibility of “pseudodeficiency alleles” is an un-
common but known phenomenon whereby some protein variants
manifest impaired activity by in vitro assays but have no demonstra-
ble phenotypic effects in vivo [Coulter-Mackie and Gagnier, 2003;
Yasuda et al., 2003; Tomatsu et al., 2009]. To understand the discre-
pancy between the predicted (normal) activity of a common pro-
tein variant and its observed (deficient) activity more fully would
requiremore definitive studies such as determination of the binding
constant (Km) for substrates, assays over the linear portion of the
product versus time curve, and careful substudies of the different
enzymatic steps for a variety of different rare and common protein
variants.
Histone Methyltransferase Activity Does Not Correlate
with Phenotypic Severity
We chose to assay EZH2 protein variants that represented a wide
variety of WS phenotypes. We had hypothesized that more severe
clinical features of WS (such as cerebral migration defects, or the
development of malignancy) might be associated with mutations
in specific protein domains that were in turn associated with more
striking alterations of histone methyltransferase activity. However,
we observed no clear correlation between these parameters. We also
observed no correlation between clinical severity and profiles of
substrate specificity (Supp. Fig. S1). Our results are consistent with
Guglielmelli et al. (2011) who observed no correlation between
EZH2 mutational status and hematologic or clinical parameters in
patients with myelofibrosis. This lack of phenotype/genotype cor-
relation suggests that factors apart from histone methyltransferase
function (such as the presence of modifier genes, other epigenetic
modifications such as H3K4 methylation, or stochastic modifiers)
might explain the phenotypic differences observed in WS patients.
Activity of accessory proteins that are absent from our in vitro as-
say might also change the conformation of the PRC2 complex and
influence the resulting phenotype. Such factors include the pres-
ence of PHF1 [Sarma et al., 2008], the activity of NF-kB [Lee et al.,
2011], WNT [Wang et al., 2010], or Akt, that modifies EZH2 post-
translationally [Cha et al., 2005]. Alternatively, the activity of WS
mutants onnonhistone substrates, such as STAT3 [Kimet al., 2013b]
or JARID2 [Sanulli et al., 2015], may be a more important determi-
nant of the ultimate phenotype of WS patients.
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